geranylgeranylacetone has been researched along with Chemical-and-Drug-Induced-Liver-Injury* in 2 studies
2 other study(ies) available for geranylgeranylacetone and Chemical-and-Drug-Induced-Liver-Injury
Article | Year |
---|---|
Geranylgeranylacetone protects against acetaminophen-induced hepatotoxicity by inducing heat shock protein 70.
Geranylgeranylacetone (GGA), an anti-ulcer drug, has been reported to induce heat shock protein (HSP) 70 in several animal organs. The present study was performed to determine whether GGA protects mouse liver against acetaminophen (APAP)-induced injury and whether it has potential as a therapeutic agent for APAP overdose. Hepatic damage was induced by single oral administration of APAP (500 mg/kg). GGA at 400 mg/kg was given orally 4 or 8h before, or 0.5h after APAP administration. Treatment of mice with GGA 4h before or 0.5h after APAP administration suppressed increases in transaminase activities and ammonia content in blood as well as hepatic necrosis. Such GGA treatment significantly increased hepatic HSP70 accumulation after APAP administration. Furthermore, GGA inhibited increases in hepatic lipid peroxide content and hepatic myeloperoxidase activity after APAP administration. In contrast, GGA neither inhibited hepatic cytochrome P450 2E1 activity nor suppressed hepatic glutathione depletion after APAP administration. The protective effect of GGA treatment 4h before APAP on hepatotoxicity induced by APAP was completely inhibited with quercetin, known as an HSP inhibitor. In conclusion, GGA has been identified as a new antidote to APAP injury, acting by induction of HSP70. The potential of GGA as a therapeutic tool is strongly supported by its ability to inhibit hepatic injury even when administered after ingestion of APAP. Topics: Acetaminophen; Alanine Transaminase; Ammonia; Analgesics, Non-Narcotic; Animals; Anti-Ulcer Agents; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP2E1; Diterpenes; Glutathione; HSP70 Heat-Shock Proteins; In Vitro Techniques; Lipid Peroxidation; Liver; Male; Mice; Microsomes, Liver; Necrosis; Peroxidase | 2006 |
Increase in hepatic tissue blood flow by teprenone.
The major objective of the present study was to evaluate mechanisms by which teprenone, a gastric mucosal protecting agent, increases hepatic mucosal blood flow using male Sprague-Dawley rats. Hepatic and gastric blood flow was measured using a laser blood flow meter after administration of teprenone, dissolved in Tween 80, into the inferior vena cava. Teprenone itself increased hepatic and gastric blood flow. It also increased hepatic and gastric blood flow in rats with acute hepatic disorders due to carbon tetrachloride (CCL4) and improved histological changes, such as inflammatory cell infiltration and fatty changes in the liver. The fact that blood endothelin (ET) concentrations increased after administration of teprenone suggest that teprenone has great affinity for ET beta receptors and shows ET beta-receptor antagonist-like effects. Hepatic blood flow decreased after administration of N-nitro-L-arginine methyl ester, a nitric oxide (NO) synthetase inhibitor, suggesting that teprenone increase NO activity. Teprenone was thought to increase hepatic and gastric blood flow by different mechanisms, because it increased gastric mucosal prostaglandin E2 concentrations. Topics: Animals; Anti-Ulcer Agents; Carbon Tetrachloride Poisoning; Chemical and Drug Induced Liver Injury; Diterpenes; Endothelin-1; Gastric Mucosa; Liver; Liver Circulation; Male; Nitric Oxide; Rats; Rats, Sprague-Dawley; Regional Blood Flow; Stimulation, Chemical | 1996 |